Free Trial
NASDAQ:TSVT

2seventy bio (TSVT) Stock Price, News & Analysis

2seventy bio logo
$5.00 0.00 (0.00%)
As of 05/13/2025

About 2seventy bio Stock (NASDAQ:TSVT)

Key Stats

Today's Range
$5.00
$5.00
50-Day Range
$4.94
$5.00
52-Week Range
$2.29
$5.30
Volume
N/A
Average Volume
639,211 shs
Market Capitalization
$266.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Hold

Company Overview

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Receive TSVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter.

TSVT Stock News Headlines

Chaotic markets? No worries!
As you may have seen over the last few weeks, I've been giving out special daily setups on my favorite ticker. We’ve been taking these setups @ 10AM and so far, we've posted 28 different payouts … Each of which were delivered at exactly 4PM as the market closed. You see, these setups require zero oversight and have shown the power to deliver in the most chaotic market conditions. And after a few weeks of fine-tuning … I knew it was time to let you in on The 4 PM Payout Plan. That's why Jack Carter and I pulled back the curtain to reveal how we've been able to nail in a 96% win rate in the same window the market lost 11 trillion dollars in value.
2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year
2seventy Bio price target lowered to $5 from $6 at Morgan Stanley
See More Headlines

TSVT Stock Analysis - Frequently Asked Questions

2seventy bio's stock was trading at $2.94 at the start of the year. Since then, TSVT shares have increased by 70.1% and is now trading at $5.00.
View the best growth stocks for 2025 here
.

2seventy bio, Inc. (NASDAQ:TSVT) issued its quarterly earnings data on Wednesday, May, 7th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.11. The firm earned $22.94 million during the quarter, compared to analyst estimates of $13.96 million. 2seventy bio had a negative trailing twelve-month return on equity of 53.65% and a negative net margin of 207.25%.

Top institutional investors of 2seventy bio include Goldman Sachs Group Inc. (8.80%), Beryl Capital Management LLC (7.98%), Groupe la Francaise (0.90%) and Charles Schwab Investment Management Inc. (0.79%). Insiders that own company stock include Kynam Capital Management, Lp, Casdin Capital, Llc, William D Baird III, Nick Leschly, Victoria Eatwell, Jessica Snow, Philip D Gregory, Nicola Heffron, Marcela V Maus and Global Healthcare Master Kynam.
View institutional ownership trends
.

Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that 2seventy bio investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Home Depot (HD), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

Last Earnings
5/07/2025
Today
6/17/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TSVT
Fax
N/A
Employees
440
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
0.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$217.57 million
Net Margins
-207.25%
Pretax Margin
-207.25%

Debt

Sales & Book Value

Annual Sales
$48.37 million
Price / Cash Flow
N/A
Book Value
$5.04 per share
Price / Book
0.99

Miscellaneous

Free Float
47,874,000
Market Cap
$266.15 million
Optionable
Optionable
Beta
1.04
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:TSVT) was last updated on 6/17/2025 by MarketBeat.com Staff
From Our Partners